The Swiss stock market finished weaker on Monday, following the results of the French and Greek elections over the weekend. The market managed to recover from the session lows, but was unable to make it into positive territory, largely due to weakness in shares of Roche.
Investors remained cautious due to the uncertainty about the European debt crisis after the elections. The situation in Greece is currently seen as a greater risk than France.
The Swiss Market Index declined by 0.27 percent Monday and finished at 6,040.18. The Swiss Leader Index dipped by 0.02 percent and the Swiss Performance Index fell by 0.16 percent.
Shares of index heavyweight Roche dropped by 3.5 percent Monday. The pharmaceutical company surprisingly announced that it has stopped a study of dalcetrapib, due to disappointing results. The drug was expected to have a sales potential of several billion francs.
Novartis climbed by 0.6 percent. The company said results from a late-stage study showed its pasireotide LAR (long-acting release) to be more effective than the current standard medical therapy in patients with acromegaly - a rare hormonal disorder. The study met its primary endpoint.
For comments and feedback contact: editorial@rttnews.com
Market Analysis
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.